A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Certain foods can worsen GI side effects from GLP-1 durgs. Learn which foods to avoid and which to choose instead.

HealthDay News — The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a research ...

RAs, might offer new ways to reduce dementia risk. Discover the latest research and what it means for Alzheimer's treatment.

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

A new international clinical trial has shown that the oral form of semaglutide, a medication already known for managing type ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...